Cargando…

Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia

BACKGROUND: Antibiotic treatment of community-acquired pneumonia (CAP) in children remains mostly empirical because clinical and paraclinical findings poorly discriminate the principal causes of CAP. Fast response to beta-lactam treatment can be considered a proxy of pneumococcal aetiology. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Jérémie F., Leis, Alexander, Lecarpentier, Thibault, Raymond, Josette, Gendrel, Dominique, Chalumeau, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355171/ https://www.ncbi.nlm.nih.gov/pubmed/22615848 http://dx.doi.org/10.1371/journal.pone.0036927

Ejemplares similares

Beta-Lactam Plus Macrolide for Patients Hospitalized With Community-Acquired Pneumonia: Difference Between Autumn and Spring
por: Kim, Yoonjung, et al.
Publicado: (2022)

Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia
por: Self, Wesley H., et al.
Publicado: (2017)

Role of procalcitonin in diagnosis of community acquired pneumonia in Children
por: Ratageri, Vinod H., et al.
Publicado: (2022)

The effect of vitamin C on procalcitonin biomarker in community‐acquired pneumonia
por: Nikzad, Mahsa, et al.
Publicado: (2021)

Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia
por: Andrijevic, Ilija, et al.
Publicado: (2014)

Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia
por: Stockmann, Chris, et al.
Publicado: (2018)

Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review
por: Al-Salloum, Jumana, et al.
Publicado: (2021)

ROLE OF PROCALCITONIN IN PATIENTS WITH COVID-19 AND HOSPITAL-ACQUIRED PNEUMONIA
por: KUMAR, MYTHRI ANIL, et al.
Publicado: (2022)

Procalcitonin, a marker of bacterial infection
por: Gendrel, D., et al.
Publicado: (1997)

Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD
por: Çolak, Ayfer, et al.
Publicado: (2017)

Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD
por: Bafadhel, Mona, et al.
Publicado: (2011)

Usefulness of Plasma Procalcitonin to Predict Severity in Elderly Patients with Community-Acquired Pneumonia
por: Kim, Ji Hye, et al.
Publicado: (2013)

CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia
por: Banerjee, Ritu
Publicado: (2021)

High serum procalcitonin concentrations in patients with sepsis and infection
por: Assicot, M., et al.
Publicado: (1993)

Value of procalcitonin as a biomarker for postoperative hospital-acquired pneumonia after abdominal surgery
por: Abu Elyazed, Mohamed M, et al.
Publicado: (2017)

Comparative Effectiveness of β-lactams Vs Azithromycin for Treatment of Outpatient Pediatric Community-acquired Pneumonia
por: Handy, Lori, et al.
Publicado: (2017)

Correlation between plasma peroxides and procalcitonin levels in patients with severe streptococcal community acquired pneumonia
por: Borrelli, E, et al.
Publicado: (2002)

Role of C-Reactive Protein and Procalcitonin in Differentiation of Tuberculosis from Bacterial Community Acquired Pneumonia
por: Kang, Young Ae, et al.
Publicado: (2009)

Procalcitonin guidance significantly reduces antibiotic duration in community-acquired pneumonia: the 'ProCAP' study
por: Christ-Crain, M, et al.
Publicado: (2005)

Diagnostic and Prognostic Values of Admission Procalcitonin Levels in Community–Acquired Pneumonia in an Intensive Care Unit
por: Boussekey, N., et al.
Publicado: (2005)

The potential of molecular diagnostics and serum procalcitonin levels to change the antibiotic management of community-acquired pneumonia
por: Gilbert, David, et al.
Publicado: (2016)

Procalcitonin Is Useful for Evaluating Patients with Ambiguous Presentation and for Early Discontinuation of Antibiotics in Community-acquired Pneumonia
por: Schuetz, Philipp
Publicado: (2020)

Diagnostic and Prognostic Roles of Procalcitonin and Other Tools in Community-Acquired Pneumonia: A Narrative Review
por: Ozbay, Sedat, et al.
Publicado: (2023)

Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis
por: Liu, Sitong, et al.
Publicado: (2019)

Predicting Oral Beta-lactam susceptibilities against Streptococcus pneumoniae
por: Murphy, Mark E., et al.
Publicado: (2021)

Utilization of serum procalcitonin as a biomarker in the diagnosis and treatment of children with bacterial hospital-acquired pneumonia
por: Wang, Wenlong, et al.
Publicado: (2020)

Doxycycline vs. macrolides in combination with a β-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients
por: Aldhahri, Raghad K., et al.
Publicado: (2022)

Procalcitonin is not an independent predictor of 30-day mortality, albeit predicts pneumonia severity in patients with pneumonia acquired outside the hospital
por: Akagi, Takanori, et al.
Publicado: (2019)

Can we recognize severe community-acquired pneumonia without pneumonia severity index? Use of modified qSOFA with procalcitonin
por: Güleç, Tolgahan, et al.
Publicado: (2023)

Beta lactam hypersensitivities
por: Azoury, Marie Eliane*, et al.
Publicado: (2014)

1336. Impact of Procalcitonin-Guided Antibiotic Management in Chronic Obstructive Pulmonary Disease Exacerbation and Community-Acquired Pneumonia
por: Triner, Molly, et al.
Publicado: (2019)

Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate
por: Chiotos, Kathleen, et al.
Publicado: (2021)

Diagnostic Accuracy of Routinely Available Biomarkers to Predict Bacteremia in Children With Community-Acquired Pneumonia: A Secondary Analysis of the GPIP/ACTIV Pneumonia Study in France, 2009–2018
por: Dudognon, Danaé, et al.
Publicado: (2021)

Association of serum procalcitonin and C-reactive protein levels with CURB-65 criteria among patients with community-acquired pneumonia
por: Keramat, Fariba, et al.
Publicado: (2018)

99. Comparison of Procalcitonin Testing to a Targeted Audit-and Feedback Strategy on Prescribed Durations of Therapy for Community-Acquired Pneumonia
por: Clark, Lauren, et al.
Publicado: (2020)

Heparin-binding protein and procalcitonin in the diagnosis of pathogens causing community-acquired pneumonia in adult patients: a retrospective study
por: Cai, Rentian, et al.
Publicado: (2021)

Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis
por: Lee, Jong Hoo, et al.
Publicado: (2017)

216. Step-down Therapy With Oral Fluoroquinolones vs. Oral β-Lactams for Hospitalized Adult Patients with Community-Acquired Pneumonia: A Multi-Hospital Cohort Study
por: Petty, Lindsay, et al.
Publicado: (2018)

Impact of Procalcitonin Guidance on the Management of Adults Hospitalized with Pneumonia
por: Walsh, Thomas, et al.
Publicado: (2017)

Clinical history in suspected cases of immediate allergy to beta-lactam
por: Rosman, Yossi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bahl4mtslno5d8itedhs0qe9l3